{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:42:13Z","timestamp":1790199733497,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40264-024-01415-7","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:01:55Z","timestamp":1712908915000},"page":"617-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy"],"prefix":"10.1007","volume":"47","author":[{"given":"Brandon W.","family":"Lennep","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasu","family":"Poondru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke D.","family":"Looney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judeth J.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"1415_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1415_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer 2022. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 10 Apr 2023."},{"issue":"Suppl. 4","key":"1415_CR3","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1093\/fampra\/cmu059","volume":"32","author":"HW Chin","year":"2015","unstructured":"Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: epidemiology, pathology, and screening. Fed Pract. 2015;32(Suppl. 4):41S-44S.","journal-title":"Fed Pract"},{"issue":"2","key":"1415_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdx742","volume":"29","author":"A Pettersson","year":"2018","unstructured":"Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx742.","journal-title":"Ann Oncol"},{"key":"1415_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"key":"1415_CR6","unstructured":"Astellas Inc. Highlights of prescribing information: XTANDI (enzalutamide) capsules, for oral use 2022. Available from: https:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-WPI.pdf. [Accessed 10 May 2023]."},{"issue":"1","key":"1415_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122\u20139. https:\/\/doi.org\/10.1111\/bcp.13425.","journal-title":"Br J Clin Pharmacol"},{"key":"1415_CR8","unstructured":"European Medicines Agency. XTANDI (enzalutamide). Summary of product characteristics 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf. [Accessed 29 May 2022]."},{"key":"1415_CR9","unstructured":"Drugs.com. Available from: https:\/\/www.drugs.com. [Accessed 5 Jan 2024]."},{"key":"1415_CR10","unstructured":"Lexicomp. Drug interactions. Available from: http:\/\/online.lexi.com. [Accessed 5 Jan 2024]."},{"key":"1415_CR11","unstructured":"Prescribers' Digital Reference. 2023. Available from: https:\/\/pdr.net\/. [Accessed 5 Jan 2024]."},{"issue":"10","key":"1415_CR12","doi-asserted-by":"publisher","first-page":"8559","DOI":"10.1007\/s00520-022-07235-8","volume":"30","author":"N Tsoukalas","year":"2022","unstructured":"Tsoukalas N, Brito-Dellan N, Font C, Butler T, Rojas-Hernandez CM, Butler T, et al. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022;30(10):8559\u201373. https:\/\/doi.org\/10.1007\/s00520-022-07235-8.","journal-title":"Support Care Cancer"},{"issue":"12","key":"1415_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"11","key":"1415_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","volume":"57","author":"ER Bates","year":"2011","unstructured":"Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.024.","journal-title":"J Am Coll Cardiol"},{"key":"1415_CR15","doi-asserted-by":"publisher","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23). https:\/\/doi.org\/10.3390\/ijms222312808.","DOI":"10.3390\/ijms222312808"},{"key":"1415_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119\u201337. https:\/\/doi.org\/10.1146\/annurev.med.56.082103.104724.","journal-title":"Annu Rev Med"},{"key":"1415_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejps.2019.01.024","volume":"130","author":"VM Lauschke","year":"2019","unstructured":"Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019;130:65\u201377. https:\/\/doi.org\/10.1016\/j.ejps.2019.01.024.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1415_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2165\/00003088-199732030-00004","volume":"32","author":"RJ Bertz","year":"1997","unstructured":"Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210\u201358. https:\/\/doi.org\/10.2165\/00003088-199732030-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"5439","key":"1415_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.286.5439.487","volume":"286","author":"WE Evans","year":"1999","unstructured":"Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487\u201391. https:\/\/doi.org\/10.1126\/science.286.5439.487.","journal-title":"Science"},{"issue":"3","key":"1415_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"International Transporter Consortium","year":"2010","unstructured":"International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336. https:\/\/doi.org\/10.1038\/nrd3028.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1415_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","volume":"83","author":"Y Chen","year":"2012","unstructured":"Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83(8):1112\u201326. https:\/\/doi.org\/10.1016\/j.bcp.2012.01.030.","journal-title":"Biochem Pharmacol"},{"issue":"18","key":"1415_CR22","doi-asserted-by":"publisher","first-page":"14581","DOI":"10.1074\/jbc.M010173200","volume":"276","author":"A Geick","year":"2001","unstructured":"Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581\u20137. https:\/\/doi.org\/10.1074\/jbc.M010173200.","journal-title":"J Biol Chem"},{"issue":"5","key":"1415_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/87912","volume":"7","author":"TW Synold","year":"2001","unstructured":"Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7(5):584\u201390. https:\/\/doi.org\/10.1038\/87912.","journal-title":"Nat Med"},{"issue":"4","key":"1415_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrd753","volume":"1","author":"TM Willson","year":"2002","unstructured":"Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1(4):259\u201366. https:\/\/doi.org\/10.1038\/nrd753.","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"1415_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1415_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"13","key":"1415_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"issue":"5","key":"1415_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"issue":"16","key":"1415_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"1415_CR30","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 10 Apr 2023."},{"issue":"9724","key":"1415_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet. 2010;375(9724):1437\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(10)60172-9.","journal-title":"Lancet"},{"issue":"10","key":"1415_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J-S, Beddo V, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043\u201355. https:\/\/doi.org\/10.1007\/s40262-015-0271-5.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1415_CR33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt J-S, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057\u201369. https:\/\/doi.org\/10.1007\/s40262-015-0283-1.","journal-title":"Clin Pharmacokinet"},{"key":"1415_CR34","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research Application Number: 203415Orig1s000. Clin Pharmacol Biopharm Rev. 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf. Accessed 28 Jun 2023."},{"issue":"5","key":"1415_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/cts.13229","volume":"15","author":"S Poondru","year":"2022","unstructured":"Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15(5):1131\u201342. https:\/\/doi.org\/10.1111\/cts.13229.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1415_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bcp.2005.06.018","volume":"70","author":"N Albermann","year":"2005","unstructured":"Albermann N, Schmitz-Winnenthal FH, Z\u2019Graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1\/ABCB1, MRP1\/ABCC1, MRP2\/ABCC2, BCRP\/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70(6):949\u201358. https:\/\/doi.org\/10.1016\/j.bcp.2005.06.018.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1415_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/annonc\/mdt571","volume":"25","author":"CN Sternberg","year":"2014","unstructured":"Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014;25(2):429\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdt571.","journal-title":"Ann Oncol"},{"issue":"2","key":"1415_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdv542","volume":"27","author":"JN Graff","year":"2016","unstructured":"Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286\u201394. https:\/\/doi.org\/10.1093\/annonc\/mdv542.","journal-title":"Ann Oncol"},{"issue":"3","key":"1415_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","volume":"24","author":"DE Spratt","year":"2021","unstructured":"Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647\u201361. https:\/\/doi.org\/10.1038\/s41391-021-00328-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1415_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07453-0","author":"F Boujonnier","year":"2023","unstructured":"Boujonnier F, Lemaitre F, Scailteux L-M. Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07453-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1415_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11\u201327. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03671.x.","journal-title":"Epilepsia"},{"issue":"6","key":"1415_CR42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","volume":"17","author":"ND Shore","year":"2022","unstructured":"Shore ND, Morgans AK, El-Haddad G, Srinivas S, Abramowitz M. Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams. Target Oncol. 2022;17(6):709\u201325. https:\/\/doi.org\/10.1007\/s11523-022-00925-7.","journal-title":"Target Oncol"},{"issue":"9","key":"1415_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17425255.2022.2122812","volume":"18","author":"D Conde-Estevez","year":"2022","unstructured":"Conde-Estevez D, Henriquez I, Munoz-Rodriguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2022;18(9):601\u201313. https:\/\/doi.org\/10.1080\/17425255.2022.2122812.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1415_CR44","doi-asserted-by":"publisher","first-page":"175883592199858","DOI":"10.1177\/1758835921998586","volume":"13","author":"F Saad","year":"2021","unstructured":"Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021;13:1758835921998586. https:\/\/doi.org\/10.1177\/1758835921998586.","journal-title":"Ther Adv Med Oncol."},{"key":"1415_CR45","unstructured":"Myovant Sciences Inc. Highlights of prescribing information: Orgovyx (relugolix) tablets, for oral use 2023. Available from: https:\/\/www.orgovyx.com\/content\/pdfs\/orgovyx-prescribing-information.pdf. Accessed 10 Apr 2023."},{"issue":"23","key":"1415_CR46","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187\u201396. https:\/\/doi.org\/10.1056\/NEJMoa2004325.","journal-title":"N Engl J Med"},{"issue":"3","key":"1415_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clgc.2023.03.009","volume":"21","author":"DJ George","year":"2023","unstructured":"George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, et al. Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023;21(3):383-92.e2. https:\/\/doi.org\/10.1016\/j.clgc.2023.03.009.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"1415_CR48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290\u2013314. https:\/\/doi.org\/10.1002\/cncr.28509.","journal-title":"Cancer"},{"issue":"1","key":"1415_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","volume":"39","author":"AK Morgans","year":"2021","unstructured":"Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021;39(1):52\u201362. https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.003.","journal-title":"Urol Oncol"},{"issue":"9859","key":"1415_CR50","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128. https:\/\/doi.org\/10.1016\/S0140-6736(12)61728-0.","journal-title":"Lancet"},{"issue":"5","key":"1415_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","volume":"19","author":"N Mackman","year":"2020","unstructured":"Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov. 2020;19(5):333\u201352. https:\/\/doi.org\/10.1038\/s41573-020-0061-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1415_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100029","volume":"2","author":"A Bellia","year":"2021","unstructured":"Bellia A, Della-Morte D, Di Daniele N, Lauro D. Drug interactions of direct oral anticoagulants in elderly patients with cardiometabolic diseases. Curr Res Pharmacol Drug Discov. 2021;2: 100029. https:\/\/doi.org\/10.1016\/j.crphar.2021.100029.","journal-title":"Curr Res Pharmacol Drug Discov."},{"key":"1415_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10928-023-09867-7","volume":"50","author":"Y Otsuka","year":"2023","unstructured":"Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, Minematsu T. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn. 2023;50:365\u201376. https:\/\/doi.org\/10.1007\/s10928-023-09867-7.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1415_CR54","unstructured":"Boehringer Ingelheim Inc. Highlights of prescribing information: Pradaxa (dabigatran etexilate) capsules, for oral use 2021. Available from: https:\/\/content.boehringer-ingelheim.com\/DAM\/c669f898-0c4e-45a2-ba55-af1e011fdf63\/pradaxa%20capsules-us-pi.pdf. Accessed 10 Apr 2023."},{"key":"1415_CR55","unstructured":"Bristol-Myers Squibb Inc. Highlights of prescribing information: coumadin (warfarin sodium) tablets, for oral use 2019. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_coumadin.pdf. Accessed 10 Apr 2023."},{"issue":"9038","key":"1415_CR56","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(96)09457-3.","journal-title":"Lancet"},{"issue":"17","key":"1415_CR57","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"I Iakovou","year":"2005","unstructured":"Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126\u201330. https:\/\/doi.org\/10.1001\/jama.293.17.2126.","journal-title":"JAMA"},{"issue":"16","key":"1415_CR58","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","volume":"53","author":"JW van Werkum","year":"2009","unstructured":"van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399\u2013409. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.055.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1415_CR59","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","volume":"30","author":"S Schulz","year":"2009","unstructured":"Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehp275.","journal-title":"Eur Heart J"},{"issue":"11","key":"1415_CR60","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"issue":"20","key":"1415_CR61","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136(20):1955\u201375. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031164.","journal-title":"Circulation"},{"key":"1415_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091218","author":"MB Shah","year":"2022","unstructured":"Shah MB. Inhibition of CYP2C8 by acyl glucuronides of gemfibrozil and clopidogrel: pharmacological significance, progress and challenges. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12091218.","journal-title":"Biomolecules"},{"key":"1415_CR63","unstructured":"Sanofi Inc. Highlights of prescribing information: PLAVIX (clopidogrel tablets) for oral use 2022. Available from: https:\/\/products.sanofi.us\/plavix\/plavix.pdf. Accessed 10 Apr 2023."},{"key":"1415_CR64","unstructured":"AstraZeneca Inc. Highlights of prescribing information: BRILINTA (ticagrelor) tablets, for oral use. 2022. Available from: https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/565ceafd-fbe3-4573-9c39-19280af566ec\/565ceafd-fbe3-4573-9c39-19280af566ec_viewable_rendition__v.pdf. Accessed 10 Apr 2023."},{"issue":"5","key":"1415_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","volume":"257","author":"W Burger","year":"2005","unstructured":"Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257(5):399\u2013414. https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01477.x.","journal-title":"J Intern Med"},{"issue":"22","key":"1415_CR66","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith Jr","year":"2011","unstructured":"Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458\u201373. https:\/\/doi.org\/10.1161\/CIR.0b013e318235eb4d.","journal-title":"Circulation"},{"issue":"2","key":"1415_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.cir.101.2.207","volume":"101","author":"DJ Maron","year":"2000","unstructured":"Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207\u201313. https:\/\/doi.org\/10.1161\/01.cir.101.2.207.","journal-title":"Circulation"},{"key":"1415_CR68","unstructured":"Parke-Davis Div of Pfizer Inc. Highlights of prescribing information: LIPITOR (atorvastin calcium) tablets, for oral use 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&type=display. Accessed 10 Apr 2023."},{"key":"1415_CR69","unstructured":"Organon Inc. Highlights of prescribing information: ZOCOR (simvastatin) tablets, for oral use 2022. Available from: https:\/\/www.organon.com\/product\/usa\/pi_circulars\/z\/zocor\/zocor_pi.pdf. Accessed 10 Apr 2023."},{"key":"1415_CR70","unstructured":"Lupin Inc. Lovastatin tablets USP 2021. Available from: https:\/\/www.lupin.com\/US\/wp-content\/uploads\/2020\/12\/pi-lovastatin-tabs-usp-1-2021.pdf. Accessed 10 Apr 2023."},{"key":"1415_CR71","unstructured":"Novartis Inc. Lescol XL (fluvastatin) package insert. 2017. Available from: https:\/\/www.novartis.com\/sg-en\/sites\/novartis_sg\/files\/LESCOL%20%2080mg%20PI%20Decl2017.SIN_.pdf. Accessed 10 Apr 2023."},{"issue":"1","key":"1415_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/2042098612474293","volume":"4","author":"RN Lowe","year":"2013","unstructured":"Lowe RN, Marrs JC, Saseen JJ. Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. Ther Adv Drug Saf. 2013;4(1):9\u201317. https:\/\/doi.org\/10.1177\/2042098612474293.","journal-title":"Ther Adv Drug Saf."},{"issue":"1","key":"1415_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117\u201325. https:\/\/doi.org\/10.1111\/j.1472-8206.2004.00299.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"1415_CR74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152\u201360. https:\/\/doi.org\/10.1016\/s0002-9149(03)00530-7.","journal-title":"Am J Cardiol"},{"issue":"12","key":"1415_CR75","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jacc.2013.11.007","volume":"63","author":"AS Go","year":"2014","unstructured":"Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12):1230\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.007.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1415_CR76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archinte.162.4.405","volume":"162","author":"DA Flockhart","year":"2002","unstructured":"Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405\u201312. https:\/\/doi.org\/10.1001\/archinte.162.4.405.","journal-title":"Arch Intern Med"},{"key":"1415_CR77","unstructured":"Pfizer Laboratories Div Pfizer Inc. Highlights of prescribing information: NORVASC (amlodipine besylate) tablets for oral administration 2019. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed&type=display. Accessed 10 Apr 2023."},{"issue":"14","key":"1415_CR78","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/01.cir.97.14.1411","volume":"97","author":"NJ Brown","year":"1998","unstructured":"Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411\u201320. https:\/\/doi.org\/10.1161\/01.cir.97.14.1411.","journal-title":"Circulation"},{"key":"1415_CR79","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/VHRM.S31578","volume":"8","author":"G Leonetti","year":"2012","unstructured":"Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vasc Health Risk Manag. 2012;8:307\u201322. https:\/\/doi.org\/10.2147\/VHRM.S31578.","journal-title":"Vasc Health Risk Manag."},{"issue":"17","key":"1415_CR80","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","volume":"138","author":"M Lei","year":"2018","unstructured":"Lei M, Wu L, Terrar DA, Huang CL. Modernized classification of cardiac antiarrhythmic drugs. Circulation. 2018;138(17):1879\u201396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035455.","journal-title":"Circulation"},{"issue":"1","key":"1415_CR81","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08998280.2003.11927893","volume":"16","author":"A Barreras","year":"2003","unstructured":"Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16(1):123\u20136. https:\/\/doi.org\/10.1080\/08998280.2003.11927893.","journal-title":"Proc (Bayl Univ Med Cent)."},{"issue":"Suppl. 2","key":"1415_CR82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4137\/CMC.S29735","volume":"9","author":"AM Szema","year":"2015","unstructured":"Szema AM, Dang S, Li JC. Emerging novel therapies for heart failure. Clin Med Insights Cardiol. 2015;9(Suppl. 2):57\u201364. https:\/\/doi.org\/10.4137\/CMC.S29735.","journal-title":"Clin Med Insights Cardiol."},{"key":"1415_CR83","doi-asserted-by":"publisher","first-page":"1102521","DOI":"10.3389\/fcvm.2023.1102521","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Zou Y, Li Y, Wang H, Sun W, Liu B. The history and mystery of sacubitril\/valsartan: from clinical trial to the real world. Front Cardiovasc Med. 2023;10:1102521. https:\/\/doi.org\/10.3389\/fcvm.2023.1102521.","journal-title":"Front Cardiovasc Med."},{"issue":"12","key":"1415_CR84","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1415_CR85","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ejhf.31","volume":"16","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail. 2014;16(2):143\u201350. https:\/\/doi.org\/10.1111\/ejhf.31.","journal-title":"Eur J Heart Fail"},{"key":"1415_CR86","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","volume":"1","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. https:\/\/doi.org\/10.1038\/nrdp.2015.19.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1415_CR87","doi-asserted-by":"publisher","first-page":"18063","DOI":"10.1038\/s41598-018-36212-7","volume":"8","author":"F Yang","year":"2018","unstructured":"Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, et al. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep. 2018;8(1):18063. https:\/\/doi.org\/10.1038\/s41598-018-36212-7.","journal-title":"Sci Rep"},{"issue":"4","key":"1415_CR88","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500X.85934","volume":"2","author":"DJ Dave","year":"2011","unstructured":"Dave DJ. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011;2(4):230\u20135. https:\/\/doi.org\/10.4103\/0976-500X.85934.","journal-title":"J Pharmacol Pharmacother"},{"issue":"4","key":"1415_CR89","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jdi.12644","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416\u201327. https:\/\/doi.org\/10.1111\/jdi.12644.","journal-title":"J Diabetes Investig."},{"key":"1415_CR90","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/jncimonographs\/lgh031","volume":"32","author":"A Rao","year":"2004","unstructured":"Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;32:150\u20137. https:\/\/doi.org\/10.1093\/jncimonographs\/lgh031.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"1415_CR91","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387\u2013401. https:\/\/doi.org\/10.3390\/neurolint13030038.","journal-title":"Neurol Int"},{"issue":"3","key":"1415_CR92","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1081\/clt-120037428","volume":"42","author":"GK Isbister","year":"2004","unstructured":"Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277\u201385. https:\/\/doi.org\/10.1081\/clt-120037428.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"1","key":"1415_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.13m08397","volume":"75","author":"IM van Haelst","year":"2014","unstructured":"van Haelst IM, van Klei WA, Doodeman HJ, Warnier MJ, De Bruin ML, Kalkman CJ, Egberts TC. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. J Clin Psychiatry. 2014;75(1):15\u201321. https:\/\/doi.org\/10.4088\/JCP.13m08397.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1415_CR94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/jcp.0b013e318160738e","volume":"28","author":"J Raskin","year":"2008","unstructured":"Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32\u20138. https:\/\/doi.org\/10.1097\/jcp.0b013e318160738e.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1415_CR95","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000000309.","journal-title":"J Urol"},{"key":"1415_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euros.2022.10.008","volume":"46","author":"B Welk","year":"2022","unstructured":"Welk B, McClure JA. The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia. Eur Urol Open Sci. 2022;46:22\u20139. https:\/\/doi.org\/10.1016\/j.euros.2022.10.008.","journal-title":"Eur Urol Open Sci."},{"issue":"14","key":"1415_CR97","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"42","author":"DR Guay","year":"2003","unstructured":"Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243\u201385. https:\/\/doi.org\/10.2165\/00003088-200342140-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1415_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.035.","journal-title":"Eur Urol"},{"issue":"7","key":"1415_CR99","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613\u201324. https:\/\/doi.org\/10.1016\/S0025-6196(11)60750-7.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl._7","key":"1415_CR100","first-page":"S713","volume":"33","author":"SEH Detert Oude Weme","year":"2022","unstructured":"Detert Oude Weme SEH, Vervenne WL, Imhoz ALT, Cremers RGHM, van Berlo-van de Laar IFR, Jansman FGA, et al. Assessment of the pharmacokinetic interaction of enzalutamide with oxycodone in men with prostate cancer: the ENZYME study. Ann Oncol. 2022;33(Suppl._7):S713-42.","journal-title":"Ann Oncol"},{"issue":"1","key":"1415_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27\u201337. https:\/\/doi.org\/10.5009\/gnl15502.","journal-title":"Gut Liver."},{"key":"1415_CR102","unstructured":"Covis Pharma Inc. Highlights of prescribing infomration: Prilosec (omeprazole magnesium) for delayed-release oral suspension 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=b6761f84-53ac-4745-a8c8-1e5427d7e179&type=display. Accessed 30 Apr 2023."},{"issue":"4","key":"1415_CR103","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1023\/a:1016062508580","volume":"13","author":"H Katsuki","year":"1996","unstructured":"Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996;13(4):611\u20135. https:\/\/doi.org\/10.1023\/a:1016062508580.","journal-title":"Pharm Res"},{"issue":"1","key":"1415_CR104","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","volume":"31","author":"F Shihab","year":"2014","unstructured":"Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014;31(1):22\u201332. https:\/\/doi.org\/10.1016\/j.trim.2014.05.002.","journal-title":"Transpl Immunol"},{"issue":"6","key":"1415_CR105","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360. https:\/\/doi.org\/10.1002\/acr.24180.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"1415_CR106","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1200\/JCO.2004.08.182","volume":"22","author":"A Sparreboom","year":"2004","unstructured":"Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22(12):2489\u2013503. https:\/\/doi.org\/10.1200\/JCO.2004.08.182.","journal-title":"J Clin Oncol"},{"key":"1415_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020634","author":"G Venturella","year":"2021","unstructured":"Venturella G, Ferraro V, Cirlincione F, Gargano ML. Medicinal mushrooms: bioactive compounds, use, and clinical trials. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020634.","journal-title":"Int J Mol Sci"},{"key":"1415_CR108","unstructured":"National Cancer Institute. Prostate cancer, nutrition, and dietary supplements (PDQ) - health professional version. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/cam\/hp\/prostate-supplements-pdq. Accessed 10 Apr 2023."},{"issue":"13","key":"1415_CR109","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2217\/fon-2018-0940","volume":"15","author":"CN Sternberg","year":"2019","unstructured":"Sternberg CN. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncol. 2019;15(13):1437\u201357. https:\/\/doi.org\/10.2217\/fon-2018-0940.","journal-title":"Future Oncol"},{"issue":"5","key":"1415_CR110","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/bcp.12425","volume":"78","author":"S Kasichayanula","year":"2014","unstructured":"Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br J Clin Pharmacol. 2014;78(5):1122\u201334. https:\/\/doi.org\/10.1111\/bcp.12425.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01415-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:22:48Z","timestamp":1718608968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01415-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01415-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"25 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding was provided by Pfizer Inc. and Astellas Pharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Brandon Lennep has received consulting fees from Pfizer Inc. Jesse Mack is an employee of Astellas Pharma Inc. and was a consultant for Pfizer prior to joining Astellas Pharma Inc. Srinivasu Poondru is an employee of Astellas Pharma Inc. Brooke Looney receives research support from AstraZeneca Inc. and Pfizer Inc. and has served as a speaker for AstraZeneca Inc. Judeth Bianco is an employee of Pfizer Inc. Alicia Morgans has received consulting fees from Astellas Pharma Inc., AAA Pharma Inc., AstraZeneca Pharma LP, Bayer HealthCare Pharma LLC, Dendreon Pharma LLC, Janssen Pharma LLC, Exelixis Inc., Myovant Sciences, Inc., Merck & Co. Inc., Novartis AG, Lantheus, Telix Pharma Limited, Sanofi S.A., and Pfizer Inc., research fees from Bayer HealthCare Pharma LLC, Myovant Sciences Inc., and Pfizer Inc., and travel support from Telix Pharma Limited and Sanofi S.A. Elizabeth Hood and Monique Williams have no financial interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"BL, AM, and JB contributed to the conception of the study. All authors contributed to the design and interpretation of the results. All authors contributed to the drafting of the paper and\/or to its revision or critical review. All authors gave final approval of the version to be published and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}